Comparison the effects of carotid endarterectomy with carotid artery stenting for contralateral carotid occlusion

Yaxuan Sun1*, Yongxia Ding2, Kun Meng1, Bin Han1, Jing Wang1, Yan Han1

1 Department of Neurology, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, China, 2 College of Nursing, Shanxi Medical University, Shanxi, China

* rvlm@163.com

Abstract

Background
There have been inconsistent results regarding the use of carotid artery endarterectomy (CEA) versus carotid artery stenting (CAS) for contralateral carotid occlusion (CCO). This study aimed to determine the optimal revascularization technique for patients with CCO.

Methods
We systematically searched the PubMed, Embase, and Cochrane Library databases to identify eligible studies published from inception to January 2, 2021. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate pooled effect estimates using a random-effects model. Sensitivity, subgroup, and publication bias analyses were also performed.

Results
Six studies involving 6,953 patients were selected for inclusion in this meta-analysis. Our results showed that while CEA was not associated with an increased risk of stroke compared to CAS (OR: 1.07; 95% CI: 0.75–1.51; P = 0.713), CEA was associated with a reduced risk of death compared to CAS (OR: 0.45; 95% CI: 0.29–0.70; P < 0.001). Furthermore, there were no significant differences between CEA and CAS for the risks of myocardial infarction (OR: 1.38; 95% CI: 0.73–2.62; P = 0.319) or major adverse cardiovascular events (OR: 1.03; 95% CI: 0.56–1.88; P = 0.926). Finally, the risk of myocardial infarction for CEA versus CAS was affected by disease status, while the risk of major adverse cardiovascular events was affected by the proportions of patients with male gender, coronary artery disease, and current or prior smoking.

Conclusion
This study found that CEA and CAS resulted in similar outcomes for patients with CCO, while the risk of death was reduced in patients treated with CEA. Further high-level evidence should be collected to verify the results of this study.
Introduction

Contralateral carotid occlusion (CCO) accounts for nearly 5%–15% of carotid artery stenosis cases and has been demonstrated to be an independent risk factor for carotid endarterectomy (CEA) [1–4]. CEA is considered a gold-standard surgical technique for prevention of stroke in patients with severe stenosis or occlusion; however, the perioperative and long-term effects of CEA in patients with severe contralateral carotid stenosis or occlusion are variable [5–8]. The North American Symptomatic Carotid Endarterectomy Trial found that, though CEA was superior to medical management alone, CCO patients had a relatively high risk of perioperative stroke after CEA [9, 10], potentially because atheromatous plaques at carotid bifurcations are removed using CEA. Moreover, CEA has been shown to improve cerebral perfusion and to reduce the risk of stroke via washout of cerebral emboli from border-zone areas [11–13].

More recently, carotid artery stenting (CAS) has been introduced as an alternative treatment strategy for patients with carotid stenosis or CCO, especially for CCO patients with contraindications to CEA [14]. However, several studies have found that hemodynamic disturbances are associated with an increased risk of periprocedural stroke after CAS, always occurring within 6 hours of the procedure [15–18]. Previous systematic reviews and meta-analyses have been performed to compare the treatment effects of CEA versus CAS for patients with CCO [19, 20]. However, these two previous studies pooled only a small number of studies and were unable to clarify whether the treatment effects of CEA differed from CAS based on patient characteristics. Therefore, we performed a systematic review and meta-analysis to compare the effects of CEA versus CAS in patients with CCO.

Methods
Data sources, search strategy, and selection criteria

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement was used to guide the performing and reporting of this systematic review and meta-analysis [21]. Studies comparing the effects of CEA versus CAS in patients with CCO were considered potentially eligible for inclusion in this meta-analysis. The PubMed, Embase, and Cochrane Library databases were systematically searched for articles published from inception to January 2, 2021 using the following search terms: ("occlusion" AND "carotid" AND "contralateral") AND ("endarterectomy" OR "carotid artery stenting"). The reference lists of retrieved studies were also manually reviewed to identify any other eligible studies meeting the inclusion criteria.

Studies were included if they met the following criteria: (1) Patients: CCO; (2) Intervention: CEA; (3) Control: CAS; (4) Outcomes: stroke, death, myocardial infarction, and major adverse cardiovascular events; and (5) Study design: no restrictions on study design, including randomized controlled trials and prospective or retrospective cohort studies. The above study selection process was independently performed by two reviewers, and any disagreements were settled by group discussion until a consensus was reached.

Data collection and quality assessment

Two reviewers abstracted data and performed quality assessments for each study, and conflicts between reviewers were resolved by an additional reviewer with reference to the original article. The following items were abstracted from each study: first author’s name, publication year, country, study design, sample size, mean age, male proportion, symptomatic patients, prior transient ischemic attacks, prior stroke, coronary artery disease, hypertension, diabetes mellitus, current or prior smoking, imbalance characteristics between CEA and CSA groups, and reported outcomes. The quality of individual studies was assessed by the Newcastle-Ottawa
Scale (NOS), a comprehensive and validated tool for assessing the quality of observational studies in meta-analyses [22]. The so-called “starring system” for each study ranged from 0–9. Studies with 7–9 stars were regarded as having high quality and those with 4–6 stars were regarded as having moderate quality.

**Statistical analysis**

The effects of CEA versus CAS on the risks of stroke, death, myocardial infarction, and major adverse cardiovascular events were calculated on the basis of the events that occurred and the sample sizes in each group. Odds ratios (OR) with 95% confidence intervals (CI) were then calculated using a random-effects model [23, 24]. The I² and Q statistic were applied to assess the heterogeneity across included studies, with significant heterogeneity defined as an I² of > 50.0% or a P-value of < 0.10 [25, 26]. The robustness of the pooled conclusions was assessed using a sensitivity analysis with sequential excluding of single studies [27]. Subgroup analyses were performed based on age, male gender, disease status, coronary artery disease, hypertension, diabetes mellitus, and smoking, and the differences between subgroups were assessed using an interaction P test [28]. Both qualitative and quantitative methods were applied to assess for potential publication bias, including funnel plots and Egger’s and Begg’s tests [29, 30]. The P-values for pooled conclusions were two-sided, and the inspection level was 0.05. Statistical analyses were conducted using STATA software (version 10.0; Stata Corporation, College Station, TX, USA).

**Results**

**Search of the published literature**

An initial electronic search identified 1,354 articles, but 411 of these articles were excluded due to duplication of titles. In addition, 907 studies were excluded because of reporting on irrelevant topics. The remaining 36 studies were retrieved for full-text evaluations, and 30 of these studies were excluded because of no appropriate control (n = 18, other disease status (n = 9), or a review (n = 3). Reviewing the reference lists of relevant studies identified one other potential study, and this study was identified in an electronic search. Finally, a total of six studies were selected for the final meta-analysis [2, 31–35], with details regarding the literature search and study selection process shown in Fig 1.

**Study characteristics**

All included studies had a retrospective cohort design, and these studies involved a total of 6,953 patients with CCO. The baseline characteristics of the included studies are shown in Table 1. Four studies were conducted in the USA, one study was conducted in Italy, and the remaining study was conducted in Korea. The sample sizes ranged from 57–4,326 patients, and a total of 2,423 patients had presented with symptomatic CCO. Study quality was assessed using the NOS and the detail results are shown in Table 2, with three studies having six stars and the remaining three studies having five stars.

**Stroke**

After pooling all included studies, there was no significant difference between CEA and CAS for the risk of stroke (OR: 1.07; 95% CI: 0.75–1.51; P = 0.713; Fig 2), and no evidence of heterogeneity was observed (I² = 0.0%; P = 0.498). The sensitivity analysis found the pooled conclusion was stable (S1 Fig). Subgroup analyses found no significant differences between CEA and
CAS for the risk of stroke in any subgroup (Table 3). No significant publication bias for stroke was detected (P-value for Egger’s test: 0.511; P-value for Begg’s test: 1.000; S2 Fig).

Death
Four studies reported the effects of CEA versus CAS on the risk of death, and the summary OR indicated that CEA was associated with a reduced risk of death compared to CAS (OR: 0.45; 95% CI: 0.29–0.70; P < 0.001; Fig 3). There was no evidence of heterogeneity across included studies (I² = 0.0%; P = 0.491). Sensitivity analysis indicated no significant difference between CEA and CAS for the risk of death when removing the study conducted by Nejim et al., which specifically included a large number of patients and reported a higher incidence of death (S3 Fig). Subgroup analyses found that CEA was more protective than CAS for the risk of death in the following subgroups: average age < 70.0 years, male proportion ≥ 70.0%, coronary artery disease proportion < 40.0%, hypertension proportion ≥ 80.0%, diabetes mellitus proportion ≥ 30.0%, and smoking proportion ≥ 40.0% (Table 3). There was no significant publication bias for death (P-value for Egger’s test: 0.422; P-value for Begg’s test: 0.734; S4 Fig).
Table 1. Baseline characteristics of included studies and patients.

| Study          | Country | Study design | Sample size | Mean age (years) | Male (%) | Symptomatic patients (%) | Prior TIA (%) | Prior stroke (%) | CAD (%) | Hypertension (%) | DM (%) | Smoking (%) | Imbalance characteristics (CEA/CAS) |
|----------------|---------|--------------|-------------|------------------|----------|--------------------------|---------------|------------------|---------|------------------|--------|-------------|-----------------------------------|
| Brewster 2012  | USA     | Retrospective| 57 (18/39)  | 67.7             | 70.2     | 49.1 (8/20)              | 36.8          | 35.1             | 14.0     | 87.7             | 36.8   | 33.3        | Prior neck surgery (5.6%/46.1%)   |
| Faggioli 2013  | Italy   | Retrospective| 75 (37/38)  | 70.9             | 70.7     | 33.3 (13/12)             | NA            | NA               | 30.7    | 92.0             | 26.7   | 10.7        | Age (65.0/76.6 years), CAD (20.0%/43.2%), CRF (5.9%/24.3%) |
| Ricotta 2014   | USA     | Retrospective| 1,794 (666/1,128) | 69.9     | 63.5     | 48.7 (266/607)          | 22.0          | 30.1             | 56.7    | 85.7             | 34.0   | NA          | Symptomatic (39.9%/53.8%), CAD (52.7%/59.0%), CHF (8.4%/14.2%), diabetes (31.1%/35.7%), COPD (18.3%/22.6%), cancer (11.7%/15.1%) |
| Yang 2014      | Korea   | Retrospective| 94 (44/50)   | 64.8             | 89.7     | 35.1 (10/24)             | 20.6          | 12.4             | 47.4    | 69.1             | NA     | 62.9        | Symptomatic (22.7%/48.0%), stroke (2.3%/22.0%), CAD (61.4%/38.0%) |
| Nejim 2017     | USA     | Retrospective| 4,326 (3,274/1,052) | 68.0    | 71.0      | 28.3 (790/433)          | NA            | 47.6             | 30.8    | 89.0             | 34.5   | 85.0        | CHF (9.6%/15.6%), COPD (16.2%/20.3%), stroke (56.4%/24.0%), Symptomatic (46.8%/60.8%) |
| Turley 2019    | USA     | Retrospective| 607 (565/42) | 70.0             | 70.0     | 39.5 (NA)               | NA            | NA               | NA      | 52.9             | 28.7   | 34.9        | Baseline ipsilateral carotid stenosis (mild [1.1%/2.4%]; moderate [32.7%/16.7%]; severe [66.2%/81.0%]) |

CAD, coronary artery disease; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CRF: chronic renal failure; DM, diabetes mellitus; TIA, transient ischemic attack

https://doi.org/10.1371/journal.pone.0250580.1001

Table 2. Quality scores of included studies using Newcastle-Ottawa Scale.

| Study          | Representativeness of the exposed cohort | Selection | Ascertainment of exposure | Demonstration that outcomes was not present at start of study | Comparability on the basis of the design or analysis | Assessment of outcome | Adequate follow-up duration | Adequate follow-up rate | Overall score |
|----------------|----------------------------------------|-----------|---------------------------|-------------------------------------------------------------|---------------------------------------------------|------------------------|-----------------------------|--------------------------|---------------|
| Brewster 2012  | 0                                      | 1         | 1                         | 1                                                           | 1                                                 | 1                      | 0                           | 0                        | 5             |
| Faggioli 2013  | 0                                      | 1         | 1                         | 1                                                           | 1                                                 | 1                      | 0                           | 1                        | 6             |
| Ricotta 2014   | 1                                      | 1         | 1                         | 1                                                           | 1                                                 | 1                      | 0                           | 0                        | 6             |
| Yang 2014      | 0                                      | 0         | 1                         | 1                                                           | 1                                                 | 1                      | 0                           | 1                        | 5             |
| Nejim 2017     | 1                                      | 1         | 1                         | 1                                                           | 1                                                 | 1                      | 0                           | 0                        | 6             |
| Turley 2019    | 0                                      | 0         | 1                         | 1                                                           | 1                                                 | 1                      | 1                           | 0                        | 5             |

https://doi.org/10.1371/journal.pone.0250580.1002
The number of studies evaluating the effects of CEA versus CAS on the risks of myocardial infarction or major adverse cardiovascular events were three and three, respectively (Fig 4). There were no significant differences between CEA and CAS for the risk of myocardial infarction (OR: 1.38; 95% CI: 0.73–2.62; P = 0.319) or major adverse cardiovascular events (OR: 1.03; 95% CI: 0.56–1.88; P = 0.926). There was no evidence of heterogeneity for myocardial infarction ($I^2 = 0.0\%$; $P = 0.941$); however, there was potentially significant heterogeneity for major adverse cardiovascular events ($I^2 = 69.0\%$; $P = 0.040$). Subgroup analyses found that CEA versus CAS was not associated with the risk of myocardial infarction in any subgroup and that treatment effect differences on the risk of myocardial infarction between CEA and CAS were significantly affected by the disease status ($P = 0.048$). Moreover, CEA was associated with a reduced risk of major adverse cardiovascular events in subgroups with a male proportion of $\geq 70.0\%$, a coronary artery disease proportion of $< 40.0\%$, and a smoking proportion of $\geq 40.0\%$ (Table 3). Furthermore, the proportions of males ($P = 0.015$), patients with coronary artery disease ($P = 0.040$), and patients with current or prior smoking ($P = 0.013$) significantly affected the treatment effects of CEA versus CAS for the risk of major adverse cardiovascular events.

**Discussion**

Studies have already proposed using CAS as an alternative treatment strategy to CEA in CCO patients [36, 37]; however, inconsistent treatment results have been obtained in these studies. In this meta-analysis, a total of 6,953 patients with CCO from six retrospective studies were included, and these patients had a broad variety of characteristics. This study found no significant differences between CEA and CAS for the risk of stroke, myocardial infarction, or major adverse cardiovascular events in patients with CCO. However, CEA was associated with a reduced risk of death compared to CAS. The protective role of CEA versus CAS on the risk of...
| Outcomes | Factors | Groups | Number of studies | OR (95% CI) | P-value | I² (%) | P_G statistic | P-value between subgroups |
|----------|---------|--------|-------------------|-------------|---------|--------|--------------|-------------------------|
| Stroke   | Age (years) | ≥ 70.0 | 2 | 2.43 (0.46–13.00) | 0.298 | 0.0 | 0.360 | 0.325 |
|         |         | < 70.0 | 4 | 1.03 (0.72–1.47) | 0.877 | 0.0 | 0.464 |
|         | Male (%) | ≥ 70.0 | 5 | 0.89 (0.58–1.37) | 0.601 | 0.0 | 0.658 | 0.163 |
|         |         | < 70.0 | 1 | 1.50 (0.83–2.71) | 0.179 | - | - |
|         | Disease status | Asymptomatic | 3 | 1.29 (0.68–2.43) | 0.432 | 0.0 | 0.850 | 0.077 |
|         |         | Symptomatic | 3 | 0.58 (0.24–1.42) | 0.231 | 4.4 | 0.351 |
|         | CAD (%) | ≥ 40.0 | 2 | 1.42 (0.80–2.52) | 0.233 | 0.0 | 0.439 | 0.428 |
|         |         | < 40.0 | 3 | 0.93 (0.49–1.77) | 0.830 | 3.6 | 0.354 |
|         | Hypertension (%) | ≥ 80.0 | 4 | 1.14 (0.69–1.89) | 0.610 | 25.3 | 0.260 | 0.904 |
|         |         | < 80.0 | 2 | 0.97 (0.21–4.60) | 0.972 | 0.0 | 0.561 |
|         | DM (%) | ≥ 30.0 | 3 | 1.06 (0.70–1.61) | 0.783 | 13.6 | 0.314 | 0.544 |
|         |         | < 30.0 | 2 | 2.43 (0.46–13.00) | 0.298 | 0.0 | 0.360 |
|         | Smoking (%) | ≥ 40.0 | 2 | 0.83 (0.53–1.30) | 0.411 | 0.0 | 0.747 | 0.193 |
|         |         | < 40.0 | 3 | 2.18 (0.45–10.44) | 0.331 | 0.0 | 0.615 |
| Death   | Age (years) | ≥ 70.0 | 1 | 3.11 (0.12–79.15) | 0.492 | - | - | 0.239 |
|         |         | < 70.0 | 3 | 0.44 (0.28–0.68) | < 0.001 | 0.0 | 0.598 |
|         | Male (%) | ≥ 70.0 | 3 | 0.41 (0.26–0.67) | < 0.001 | 0.0 | 0.448 | 0.369 |
|         |         | < 70.0 | 1 | 0.70 (0.25–1.98) | 0.502 | - | - |
|         | Disease status | Asymptomatic | 2 | 0.73 (0.36–1.48) | 0.382 | 0.0 | 0.872 | 0.054 |
|         |         | Symptomatic | 2 | 0.50 (0.04–5.54) | 0.571 | 56.5 | 0.130 |
|         | CAD (%) | ≥ 40.0 | 1 | 0.70 (0.25–1.98) | 0.502 | - | - | 0.369 |
|         |         | < 40.0 | 3 | 0.41 (0.26–0.67) | < 0.001 | 0.0 | 0.448 |
|         | Hypertension (%) | ≥ 80.0 | 4 | 0.45 (0.29–0.70) | < 0.001 | 0.0 | 0.491 | - |
|         |         | < 80.0 | 0 | - | - | - | - |
|         | DM (%) | ≥ 30.0 | 3 | 0.44 (0.28–0.68) | < 0.001 | 0.0 | 0.598 | 0.239 |
|         |         | < 30.0 | 1 | 3.11 (0.12–79.15) | 0.492 | - | - |
|         | Smoking (%) | ≥ 40.0 | 1 | 0.40 (0.25–0.65) | < 0.001 | - | - | 0.525 |
|         |         | < 40.0 | 2 | 0.93 (0.08–11.42) | 0.956 | 11.0 | 0.289 |
| MI      | Age (years) | ≥ 70.0 | 0 | - | - | - | - |
|         |         | < 70.0 | 3 | 1.38 (0.73–2.62) | 0.319 | 0.0 | 0.941 |
|         | Male (%) | ≥ 70.0 | 2 | 1.31 (0.64–2.69) | 0.461 | 0.0 | 0.904 | 0.745 |
|         |         | < 70.0 | 1 | 1.70 (0.42–6.85) | 0.455 | - | - |
|         | Disease status | Asymptomatic | 2 | 0.72 (0.33–1.59) | 0.415 | 0.0 | 0.871 | 0.048 |
|         |         | Symptomatic | 2 | 5.51 (0.86–35.14) | 0.071 | 0.0 | 0.416 |
|         | CAD (%) | ≥ 40.0 | 1 | 1.70 (0.42–6.85) | 0.455 | - | - | 0.745 |
|         |         | < 40.0 | 2 | 1.31 (0.64–2.69) | 0.461 | 0.0 | 0.904 |
|         | Hypertension (%) | ≥ 80.0 | 3 | 1.38 (0.73–2.62) | 0.319 | 0.0 | 0.941 | - |
|         |         | < 80.0 | 0 | - | - | - | - |
|         | DM (%) | ≥ 30.0 | 3 | 1.38 (0.73–2.62) | 0.319 | 0.0 | 0.941 | - |
|         |         | < 30.0 | 0 | - | - | - | - |
|         | Smoking (%) | ≥ 40.0 | 1 | 1.32 (0.64–2.74) | 0.455 | - | - | 0.941 |
|         |         | < 40.0 | 1 | 1.00 (0.01–83.85) | 1.000 | - | - |

(Continued)
death was mainly detected in subgroups with an average age of < 70.0 years, a male proportion of ≥ 70.0%, a coronary artery disease proportion of < 40.0%, a hypertension proportion of ≥ 80.0%, a diabetes mellitus proportion of ≥ 30.0%, and a smoking proportion of ≥ 40.0%.

Interestingly, we also noted that CEA was associated with a reduced risk of major adverse cardiovascular events in subgroups with a male proportion of ≥ 70.0%, a coronary artery disease proportion of < 40.0%, and a smoking proportion of < 40.0%. The results of this study support the use of CEA for patients with CCO. Furthermore, this study identifies specific populations who could benefit most significantly from CEA.

Table 3. (Continued)

| Outcomes | Factors     | Groups     | Number of studies | OR (95% CI) | P-value | I² (%) | P_Q statistic | P-value between subgroups |
|-----------|-------------|------------|-------------------|-------------|---------|--------|---------------|---------------------------|
| MACE      | Age (years) | ≥ 70.0     | 1                 | 1.13 (0.33–3.82) | 0.844   | -      | -             | 0.690                     |
|           |             | < 70.0     | 2                 | 1.02 (0.48–2.19) | 0.960   | 84.1   | 0.012         |                           |
| Male (%)  | ≥ 70.0      | 2          | 0.73 (0.54–0.99)  | 0.045       | 0.0     | 0.470  | 0.015         |                           |
|           | < 70.0      | 1          | 1.55 (0.92–2.61)  | 0.099       | -       |        |               |                           |
| CAD (%)   | ≥ 40.0      | 1          | 1.55 (0.92–2.61)  | 0.099       | -       |        | 0.040         |                           |
|           | < 40.0      | 1          | 0.71 (0.52–0.97)  | 0.034       | -       |        |               |                           |
| Hypertension (%) | ≥ 80.0 | 2 | 1.02 (0.48–2.19) | 0.960 | 84.1 | 0.012 | 0.690 |
|           | < 80.0      | 1          | 1.13 (0.33–3.82)  | 0.844       | -       |        |               |                           |
| DM (%)    | ≥ 30.0      | 2          | 1.02 (0.48–2.19)  | 0.960       | 84.1    | 0.012  | 0.690         |                           |
|           | < 30.0      | 1          | 1.13 (0.33–3.82)  | 0.844       | -       |        |               |                           |
| Smoking (%)| ≥ 40.0     | 1          | 0.71 (0.52–0.97)  | 0.034       | -       |        | 0.013         |                           |
|           | < 40.0      | 2          | 1.48 (0.91–2.38)  | 0.111       | 0.0     | 0.640  |               |                           |

CAD, coronary artery disease; DM, diabetes mellitus; MACE, major adverse cardiovascular events; MI, myocardial infarction

https://doi.org/10.1371/journal.pone.0250580.t003

Fig 3. Effects of carotid endarterectomy (CEA) versus Carotid Artery Stenting (CAS) on the risk of death.

https://doi.org/10.1371/journal.pone.0250580.g003
A similar prior meta-analysis included five retrospective studies and found that CEA was associated with a reduced risk of 30-day periprocedural mortality, while the risks of stroke, myocardial infarction, and major adverse cardiovascular events were similar in the CEA and CAS groups of CCO patients [19]. Another important meta-analysis conducted by Xin et al. identified four studies and found similar conclusions [20]. Moreover, these studies pointed out that the risk of transient ischemic attacks did not statistically differ between CEA and CAS. However, these studies could not identify whether the treatment effects of CEA versus CAS differed based on patient characteristics. Furthermore, newly published articles should be included in an updated meta-analysis, and pooled results should be reevaluated. Therefore, the present systematic review and meta-analysis was performed to compare the effects of CEA versus CAS in patients with CCO using the most current literature.

There were no significant differences between CEA and CAS for the risks of stroke, myocardial infarction, or major adverse cardiovascular events. Most of the included studies reported similar conclusions; however, the study conducted by Nejim et al. found that CEA was associated with a reduced risk of major adverse cardiovascular events in comparison with CAS [34]. The beneficial effect of CEA on the risk of major adverse cardiovascular events was mainly detected in symptomatic patients. Moreover, subgroup analyses found that CEA was associated with a reduced risk of major adverse cardiovascular events in the subgroups with a male proportion of \( \geq 70.0\% \), a coronary artery disease proportion of \(< 40.0\% \), and a smoking proportion of \( \geq 40.0\% \). These findings may have resulted from the inclusion of the study conducted by Nejim et al. due to this study's large sample size and high weighting in the pooled results. Moreover, the definition of major adverse cardiovascular events differed across the included studies, which might have contributed to these results.

Similar to prior meta-analyses, we noted that CEA was associated with a reduced risk of death compared to CAS, with this significant benefit mainly observed in the subgroups of...
patients with an average age of < 70.0 years, a male proportion of ≥ 70.0%, a coronary artery disease proportion of < 40.0%, a hypertension proportion of ≥ 80.0%, a diabetes mellitus proportion of ≥ 30.0%, and a smoking proportion of ≥ 40.0%. These findings may result from CCO patients presenting with severe atherosclerosis and resultant soft plaques. In these patients, emboli can escape during CAS because this technique requires repeated passes through stenotic blood vessels and does not block blood flow. Moreover, a rejection reaction to CAS has been associated with an increased risk of mortality [38]. Moreover, the benefit effect of CEA on the risk of death mainly attribute the study conducted by Nejim et al [34], this study specifically reported the proportion of congestive heart failure, chronic obstructive pulmonary disease, and symptomatic patients in CEA group was lower than CAS group, which could explained the potential difference for the risk of death between CEA and CAS. Subgroup analyses suggested these populations could obtain more benefit from CEA than CAS in protecting against the risk of death.

Several strengths of this study should be highlighted: (1) the analysis of this study included data from a large number of patients, and the conclusions had more robustness than from any individual study; (2) there was no evidence of heterogeneity except for in major adverse cardiovascular events, which may have been explained by the various definitions used across the included studies; and (3) subgroup analyses were performed, and the results of these analyses identify specific populations who may obtain more benefit from CEA.

The limitations of this study should also be acknowledged. First, all of the included studies had a retrospective cohort design, and the characteristics of patients who underwent CEA versus CAS were not balanced, which could have affected the prognosis of these patients. Second, due to the smaller number of included studies, the results of subgroup analyses were variable and need further verification. Third, although no significant publication bias was observed, it is inevitable that some bias occurred due to the nature of an analysis based on published articles. Finally, the details analyses were restricted because pooled data from individual studies were used.

In conclusion, this study found that CEA and CAS contributed similar effects to the risks of stroke, myocardial infarction, and major adverse cardiovascular events, while CCO patients treated with CEA obtained more benefit for preventing death than those treated with CAS. Further randomized controlled trials should be performed to verify the findings of this study.

Supporting information

S1 Fig. Sensitivity analysis for stroke.
(DOCX)

S2 Fig. Funnel plot for stroke.
(DOCX)

S3 Fig. Sensitivity analysis for death.
(DOCX)

S4 Fig. Funnel plot for death.
(DOCX)

S1 Checklist.
(DOC)

Author Contributions

Conceptualization: Yaxuan Sun, Yan Han.
Data curation: Bin Han.
Formal analysis: Kun Meng.
Investigation: Kun Meng, Jing Wang.
Methodology: Yongxia Ding.
Resources: Bin Han.
Software: Yan Han.
Writing – original draft: Yaxuan Sun, Yongxia Ding.
Writing – review & editing: Yaxuan Sun.

References

1. Maatz W, Köhler J, Botsios S, John V, Walterbusch G. Risk of stroke for carotid endarterectomy patients with contralateral carotid occlusion. Ann Vasc Surg 2008; 22(1):45–51. https://doi.org/10.1016/j.avsg.2007.07.034 PMID: 18083336
2. Faggioli G, Pini R, Mauro R, Freyrie A, Gargiulo M, Stella A. Contralateral carotid occlusion in endovascular and surgical carotid revascularization: a single centre experience with literature review and meta-analysis. Eur J Vasc Endovasc Surg 2013; 46(1):10–20. https://doi.org/10.1016/j.ejvs.2013.03.021 PMID: 23639235
3. Mehta RH, Zahn R, Hochadel M, Mudra H, Ischinger T, Hauptmann KE, et al. Effectiveness and safety of carotid artery stenting for significant carotid stenosis in patients with contralateral occlusion (from the German ALKK-CAS Registry experience). Am J Cardiol 2009; 104(5):725–31. https://doi.org/10.1016/j.amjcard.2009.04.038 PMID: 19699352
4. International Carotid Stenting Study investigators, Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375(9719):985–97. https://doi.org/10.1016/S0140-6736(10)60239-5 PMID: 20189239
5. North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med. 1991; 325(7):445–453. https://doi.org/10.1056/NEJM199108153250701 PMID: 1852179
6. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995; 273(18):1421–1428. https://doi.org/10.1001/jama.1995.03520420037035 PMID: 7723155
7. European Carotid Surgery Trailist Collaborative Group. European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet. 1995; 337(8752):1235–1243.
8. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010; 376(9746):1074–1084. https://doi.org/10.1016/S0140-6736(10)61197-X PMID: 20870099
9. Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace MC, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. Stroke. 1999; 30(9):1751–1758. https://doi.org/10.1161/01.str.30.9.1751 PMID: 10471417
10. Gasecki AP, Eliasziw M, Ferguson GG, Hachinski V, Barnett HJ. Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 1995; 83(5):778–82. https://doi.org/10.3171/jns.1995.83.5.0778 PMID: 7472542
11. Barnett HJ, Gunton RW, Eliasziw M, Fleming L, Sharpe B, Gates P, et al. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA 2000; 283(11):1429–36. https://doi.org/10.1001/jama.283.11.1429 PMID: 10732932
12. Blaser T, Hofmann K, Buerger T, Effgenberger O, Wallesch CW, Goertler M. Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe...
carotid stenosis. Stroke 2002; 33(4):1057–1062. https://doi.org/10.1161/01.str.000013671.70986.39 PMID: 11935061

13. Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hyperperfusion, embolism, and ischemic stroke. Arch Neurol 1998; 55(11):1475–82. https://doi.org/10.1001/archneur.55.11.1475 PMID: 9823834

14. CMS. Gov. Centers for medicare & medicaid services. Medicare coverage database. http://www.cms.gov/medicare-coverage-database. Accessed January 16, 2021.

15. Huibers A, Calvet D, Kennedy F, Czuriga-Kovács KR, Featherstone RL, Moll FL, et al. Mechanism of procedural stroke following carotid endarterectomy or carotid artery stenting within the International Carotid Stenting Study (ICSS) randomised trial. Eur J Vasc Endovasc Surg 2015; 50(3): 281–8. https://doi.org/10.1016/j.ejvs.2015.05.017 PMID: 26160210

16. Gupta R, Abou-Chebl A, Bajzer CT, Schumacher HC, Yadav JS. Rate, predictors, and consequences of hemodynamic depression after carotid artery stenting. J Am Coll Cardiol 2006; 47(8): 1538–43. https://doi.org/10.1016/j.jacc.2005.08.079 PMID: 16630988

17. Widecka-Ostrowska K, Modrzejewski A, Goracy J. Haemodynamic depression during carotid angioplasty and stenting. Pol J Radiol 2010; 75(4):34–7. http://www.polradiol.com/fulltext.php?ICID=881338. PMID: 22802802

18. Abou-Chebl A, Yadav JS, Reginelli JP, Bajzer C, Bhatt D, Krieger DW. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: risk factors, prevention, and treatment. J Am Coll Cardiol 2004; 43(9):1596–601. https://doi.org/10.1016/j.jacc.2003.12.039 PMID: 15120817

19. Texalidakis P, Giannopoulos S, Kokkinidis DG, Karasavvidis T, Rangel-Castilla L, Reavey-Cantwell J, Carotid Artery Endarterectomy Versus Carotid Artery Stenting for Patients with Contralateral Carotid Occlusion: A Systematic Review and Meta-Analysis. World Neurosurg 2018; 120:563–571.e3. https://doi.org/10.1016/j.wneu.2018.08.183 PMID: 30189300

20. Xin WQ, Zhao Y, Ma TZ, Gao YK, Wang WH, Wang HY, et al. Comparison of postoperative results between carotid endarterectomy and carotid artery stenting for patients with contralateral carotid artery occlusion: a meta-analysis. Vascular. 2019; 27(6):595–603. https://doi.org/10.1177/1708538119841232 PMID: 31027468

21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Plos Med 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603–5. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370

23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2 PMID: 3802833

24. Ades AE, Lu G, Higgins JP. The interpretation of random-effects metaanalysis in decision models. Med Decis Making 2005; 25(6):464–54. https://doi.org/10.1177/0272989X05282643 PMID: 16282215

25. Deeks JJ, Higgins JPT, Altman DG. Analyzing data and undertaking meta-analyses. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, UK: The Cochrane Collaboration: 2008; chap 9.

26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120

27. Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull 1999; 47:15–17

28. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Metaanalysis in Context. 2nd ed. London: BMJ Books 2001, p. 285–312.

29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563

30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4):1088–1101. PMID: 7786990

31. Brewster LP, Beaulieu R, Kasirajan K, Corriere MA, Ricotta JJ 2nd, Patel S, et al. Contralateral occlusion is not a clinically important reason for choosing carotid artery stenting for patients with significant carotid artery stenosis. J Vasc Surg 2012; 56(5):1291–4; discussion 1294–5. https://doi.org/10.1016/j.jvs.2012.04.033 PMID: 22840742

32. Ricotta JJ 2nd, Upchurch GR Jr, Landis GS, Kenwood CT, Siiami FS, Tsilimparis N, et al. The influence of contralateral occlusion on results of carotid interventions from the Society for Vascular Surgery Vascular Registry. J Vasc Surg. 2014; 60(4):958–64; discussion 964–5. https://doi.org/10.1016/j.jvs.2014.04.036 PMID: 25260471
33. Yang SS, Kim YW, Kim DI, Kim KH, Jeon P, Kim GM, et al. Impact of contralateral carotid or vertebral artery occlusion in patients undergoing carotid endarterectomy or carotid artery stenting. J Vasc Surg 2014; 59(3): 749–55. https://doi.org/10.1016/j.jvs.2013.10.055 PMID: 24360588

34. Nejim B, Dakour Aridi H, Locham S, Arhuidese I, Hicks C, Malas MB. Carotid artery revascularization in patients with contralateral carotid artery occlusion: Stent or endarterectomy? J Vasc Surg 2017; 66 (6):1735–1748.e1. https://doi.org/10.1016/j.jvs.2017.04.055 PMID: 28666824

35. Turley RS, Freischlag K, Truong T, Benrashid E, Kuchibhatla M, Shortell CK, et al. Carotid stenting and endarterectomy and contralateral carotid occlusion. J Vasc Surg 2019; 70(3):824–831. https://doi.org/10.1016/j.jvs.2018.12.039 PMID: 30922764

36. Gray WA, White HJ Jr, Barrett DM, Chandran G, Turner R, Reisman M. Carotid stenting and endarterectomy: a clinical and cost comparison of revascularization strategies. Stroke 2002; 33(4):1063–1070. https://doi.org/10.1161/hs0402.105304 PMID: 11935062

37. Rajagopal V, Yadav J. Management of carotid artery disease in the high-risk patient with emphasis on the SAPPHIRE study. Curr Cardiol Rep 2007; 9(1):20–24. https://doi.org/10.1007/s11886-007-0005-x PMID: 17362680

38. Schnaudigel S, Gröschel K, Pilgram SM, Kastrup A. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke 2008; 39(6): 1911–1919. https://doi.org/10.1161/STROKEAHA.107.500603 PMID: 18388346